Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback